Opioids for restless legs syndrome

Opioids for restless legs syndrome

Author de Oliveira, Cesar Osorio Autor UNIFESP Google Scholar
Carvalho, Luciane Bizari Coin Autor UNIFESP Google Scholar
Carlos, Karla Google Scholar
Conti, Cristiane Fiquene Google Scholar
de Oliveira, Marcio Moysés Google Scholar
Prado, Lucila Bizari Fernandes. Google Scholar
Prado, Gilmar Fernandes Autor UNIFESP Google Scholar
Abstract Background Restless legs syndrome (RLS) is a distressing and common neurological disorder that may have a huge impact in the quality of life of those with frequent and intense symptoms. Patients complain of unpleasant sensations in the legs, at or before bedtime, and feel an urge to move the legs, which improves with movement, such as walking. Symptoms start with the patient at rest (e.g. sitting or lying down), and follow a circadian pattern, increasing during the evening or at night. Many pharmacological intervention are available for RLS, including drugs used to treat Parkinson's disease (L-Dopa and dopaminergic agonists), epilepsy (anticonvulsants), anxiety (benzodiazepines), and pain (opioids). Dopaminergic drugs are those most frequently used for treatment of RLS, but some patients do not respond effectively and require other medication. Opioids, a class of medications used to treat severe pain, seem to be effective in treating RLS symptoms, and are recommended for patients with severe symptoms, because RLS and pain appear to share the same mechanismin the central nervous system. All available drugs are associated to some degree with side effects, which can impede treatment. Opioids are associated with adverse events such as constipation, tolerance, and dependence. This justifies the conduct of a systematic review to ascertain whether opioids are safe and effective for treatment of RLS. Objectives To asses the effects of opioids compared to placebo treatment for restless legs syndrome in adults. Search methods We searched the Cochrane Central Register of Controlled trials, CENTRAL 2016, issue 4 and MEDLINE, EMBASE, and LILACS up to April 2016, using a search strategy adapted by Cochraneto identify randomised clinical trials. We checked the references of each study and established personal communication with other authors to identify any additional studies. We considered publications in all languages. Selection criteria Randomised controlled clinical trials of opioid treatment in adults with idiopathic RLS. Data collection and analysis Two review authors independently screened articles, independently extracted data into a standard form, and assessed for risk of bias. If necessary, they discussed discrepancies with a third researcher to resolve any doubts. Main results We included one randomised clinical trial (N = 304 randomised

204 completed

276 analysed) that evaluated opioids (prolonged release oxycodone/naloxone) versus placebo. After 12 weeks, RSL symptoms had improved more in the drug group than in the placebo group (using the IRLSSS: MD -7.0

95% CI -9.69 to -4.31 and the CGI: MD -1.11

95% CI -1.49 to -0.73). More patients in the drug group than in the placebo group were drug responders (using the IRLSSS: RR 1.82

95% CI 1.37 to 2.42 and the CGI: RR1.92

95% ICI 1.49 to 2.48). The proportion of remitters was greater in the drug group than in the placebo group (using the IRLSSS: RR 2.14

95% CI 1.45 to 3.16). Quality of life scores also improved more in the drug group than in the placebo group (MD -0.73

95% CI -1.1 to -0.36). Quality of sleep was improved more in the drug group measured by sleep adequacy (MD -0.74

95% CI -1.15 to 0.33), and sleep quantity (MD 0.89

95% CI 0.52 to 1.26). There was no difference between groups for daytime somnolence, trouble staying awake during the day, or naps during the day. More adverse events were reported in the drug group (RR 1.22

95% CI 1.07 to 1.39). The major adverse events were gastrointestinal problems, fatigue, and headache. Authors' conclusions Opioids seem to be effective for treating RLS symptoms, but there are no definitive data regarding the important problem of safety. This conclusion is based on only one study with a high dropout rate (moderate quality evidence).
Keywords Limb Movement-Disorder
Ekbom Disease
Double-Blind
Sleep
Prevalence
Iron
Epidemiology
Validation
Dopamine
Placebo
Language English
Sponsor Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Brazil
CAPES
CNPq, Brazil
Date 2016
Published in Cochrane Database Of Systematic Reviews. Hoboken, n. 6, p. CD006941, 2016.
ISSN 1469-493X (Sherpa/Romeo, impact factor)
Publisher Inst Brasileiro Pesquisa & Ensino Fisiologia Exercicio-Ibpefex
Extent CD006941
Origin http://dx.doi.org/10.1002/14651858.CD006941.pub2
Access rights Open access Open Access
Type Revisão
Web of Science ID WOS:000381106800016
URI http://repositorio.unifesp.br/handle/11600/49420

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account